Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 154

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 154
---
Costa Rica593 530 Other countries683 672 Property, plant and equipment, net3,795 3,294 Goodwill18,214 17,089 Other intangible assets, net7,162 6,684 Operating lease right-of-use assets in Other long-term assets495 449  $29,665 $27,516 

NOTE K – REVENUE We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.Three Months Ended September 30,20252024BusinessesU.S.Int'lTotalU.S.Int'lTotalEndoscopy$462 $285 $747 $417 $261 $678 Urology511 171 682 379 153 532 Neuromodulation230 63 293 211 57 268 MedSurg1,202 519 1,722 1,007 472 1,479 Interventional Cardiology Therapies256 429 686 212 449 661 Watchman470 43 512 342 38 380 Cardiac Rhythm Management354 224 578 349 213 561 Electrophysiology607 258 865 366 160 527 Cardiology1,687 954 2,641 1,269 859 2,129 Peripheral Interventions405 297 702 316 285 602 Cardiovascular2,092 1,251 3,343 1,586 1,145 2,731 Total Net Sales$3,294 $1,770 $5,065 $2,593 $1,616 $4,209 

36

Table of Contents

Nine Months Ended September 30,20252024BusinessesU.S.Int'lTotalU.S.Int'lTotalEndoscopy$1,338 $818 $2,157 $1,227 $769 $1,996 Urology1,478 514 1,992 1,098 473 1,570 Ne